CD30-Positive Lymphoproliferative Disorders: Atlas of Blood Cancer Genomes
Cutaneous CD30 positive lymphoproliferative disorders (CD30+ LPD) represent a biologically diverse group of diseases with highly variable clinical outcomes. We integrated clinical, genomic, and transcriptomic data from 91 patients across multiple institutions. Patients were stratified into two clinical risk groups based on treatment recommendations, confirming significantly worse overall survival among those requiring aggressive therapy (clinical code 1). Mutational profiling identified recurrent alterations in KDR, TET2, NCOR2, and PRDM1, implicating angiogenesis and epigenetic dysregulation in disease pathogenesis. Notably, KDR p.Q472H, previously linked to microvessel density and disease aggressiveness in solid tumors, was detected as a hotspot and trended toward higher frequency in lower-risk patients. Transcriptomic analysis revealed that high-risk patients exhibited upregulation of MYC targets, G2M checkpoint genes, and DNA repair pathways, indicating increased proliferative and oncogenic signaling in this group. Immune deconvolution further revealed an immunocompetent tumor microenvironment in favorable-outcome patients (clinical code 0) marked by higher abundance of resting dendritic cells (p<0.005). These findings highlight the heterogeneity of cutaneous CD30⁺ LPD and demonstrate that transcriptional programs and immune context may more accurately distinguish indolent from aggressive disease than mutational burden alone.
- Type: Cancer Genomics
- Archive: European Genome-phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD50000001982 | Illumina NovaSeq X | 38 | |
| EGAD50000001983 | Illumina NovaSeq X | 44 |
| Publications | Citations |
|---|---|
|
Characterising the genomic landscape of two clinical risk groups in CD30+ T-cell lymphoproliferative disorders with cutaneous involvement: a multi-institutional retrospective study.
EBioMedicine 133: 2026 106532 |
0 |
